Mesoblast gets a $110M lifeline from SurgCenter Development; uniQure still unsure if gene therapy spurred cancer event
Mesoblast faced rough waters in 2020, but on Monday were thrown a financial lifeline.
The Australian stem cell therapy player has raised $110 million in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
